Yong Loo Lin School of Medicine, Singapore.
Khoo Teck Puat Hospital, Singapore.
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231168108. doi: 10.1177/23247096231168108.
The melanocortin (3 or 4) receptor (MC3/4R) is involved in regulating satiety and body weight. Therefore, pathogenic mutation in MC3/4R is associated with severe obesity, for which bariatric surgery is one of the treatment options. However, there is limited data on whether individuals with MC3/4R mutation will have differential weight response to surgery, especially among the Asian populations-the epi-center of the evolving global obesity epidemic. From our large prospective Obesity-Metabolism & Intervention Cohort Study (OMICS; N = 654, recruited between 2007 and 2022), 5 individuals with pathogenic MC3/4R mutations ("case") were identified using candidate-genes panel next-generation sequencing (Illumina iSeq). These subjects were carefully propensity score-matched (baseline body mass index [BMI], age, sex, ethnicity, proportion with diabetes, type of bariatric surgery) in a 1:4 ratio to other controls. We performed linear mixed model analysis (for repeated measurements) to compare their longitudinal weight trajectories (percentage total weight loss, %TWL) over 12 months. The 5 cases with MC3/4R mutations were 48 ± 11 years, BMI 40.8 ± 11.2 kg/m, 60% with diabetes, and all males. Their weight at baseline (pre-op), and 6 months and 12 months after surgery were 120 ± 38, 100 ± 31, and 101 ± 30 kg, respectively. Compared with propensity score-matched controls (N = 20), linear mixed model analysis suggested no difference in surgically induced %TWL (β coefficient = -5.8 ± 3.7, = .13) over 12 months between the groups. Therefore, we conclude that rare pathogenic MC3/4R mutations do not significantly modify weight change (%TWL) in response to bariatric surgery.
黑素皮质素 (3 或 4) 受体 (MC3/4R) 参与调节饱腹感和体重。因此,MC3/4R 的致病突变与严重肥胖有关,对此,减重手术是治疗选择之一。然而,关于 MC3/4R 突变患者手术的减重反应是否存在差异,特别是在亚洲人群中(肥胖流行的全球中心),数据有限。在我们的大型前瞻性肥胖-代谢和干预队列研究(OMICS;N = 654,于 2007 年至 2022 年期间招募)中,使用候选基因panel 下一代测序(Illumina iSeq)鉴定了 5 名致病性 MC3/4R 突变患者(“病例”)。这些患者通过倾向评分匹配(基线体重指数 [BMI]、年龄、性别、种族、糖尿病比例、减重手术类型),以 1:4 的比例与其他对照组匹配。我们进行了线性混合模型分析(用于重复测量),以比较他们 12 个月的纵向体重变化轨迹(总体重减轻百分比,%TWL)。5 名 MC3/4R 突变患者的年龄为 48 ± 11 岁,BMI 为 40.8 ± 11.2 kg/m2,60%患有糖尿病,且均为男性。他们的基线(术前)体重、术后 6 个月和 12 个月的体重分别为 120 ± 38、100 ± 31 和 101 ± 30 kg。与倾向评分匹配的对照组(N = 20)相比,线性混合模型分析表明,两组在 12 个月内手术引起的 %TWL 没有差异(β系数=-5.8 ± 3.7,=.13)。因此,我们得出结论,罕见的致病性 MC3/4R 突变不会显著改变减重手术对体重变化(%TWL)的影响。